Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Mark

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Clinical Lung Cancer|June 25, 2025
Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter StudyKira-Lee Koster, Sarvaganthasenay Yohasenan, Ahmet Samil Pakmak, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 2020
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2Michael Mark, Patrizia Froesch, Eric Innocents Eboulet, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2024
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancerEnriqueta Felip, Giulio Metro, Daniel S W Tan, et al.
Lung Cancer (Amsterdam, Netherlands)|November 11, 2025
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastasesLorenz Frehner, Sämi Schär, Stefanie Hayoz, et al.
JTO Clinical and Research Reports|December 3, 2024
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line TreatmentSabine Schmid, Lisa Holer, Katrin Gysel, et al.
Molecular Metabolism|September 8, 2020
SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humansHeeyoung Chae, Robert Augustin, Eva Gatineau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2018
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)Martin Früh, Daniel C Betticher, Roger Stupp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2021
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II TrialSacha I Rothschild, Alfred Zippelius, Eric I Eboulet, et al.
Nature Communications|September 30, 2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapyDominic Schmid, Bettina Sobottka, Massimiliano Manzo, et al.
JTO Clinical and Research Reports|January 13, 2025
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World StudyLaura Moliner, Núria Zellweger, Sabine Schmid, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Clinical Lung Cancer|June 25, 2025
Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter StudyKira-Lee Koster, Sarvaganthasenay Yohasenan, Ahmet Samil Pakmak, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 2020
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2Michael Mark, Patrizia Froesch, Eric Innocents Eboulet, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2024
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancerEnriqueta Felip, Giulio Metro, Daniel S W Tan, et al.
Lung Cancer (Amsterdam, Netherlands)|November 11, 2025
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastasesLorenz Frehner, Sämi Schär, Stefanie Hayoz, et al.
JTO Clinical and Research Reports|December 3, 2024
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line TreatmentSabine Schmid, Lisa Holer, Katrin Gysel, et al.
Molecular Metabolism|September 8, 2020
SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humansHeeyoung Chae, Robert Augustin, Eva Gatineau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2018
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)Martin Früh, Daniel C Betticher, Roger Stupp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2021
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II TrialSacha I Rothschild, Alfred Zippelius, Eric I Eboulet, et al.
Nature Communications|September 30, 2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapyDominic Schmid, Bettina Sobottka, Massimiliano Manzo, et al.
JTO Clinical and Research Reports|January 13, 2025
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World StudyLaura Moliner, Núria Zellweger, Sabine Schmid, et al.
Pageof 9